1. Edwards KR, Hershey L, WrayL, Bednarczyk EM, Lichter D, Johnson S.  Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies:  A 12-Week Interim Analysis.Dementia and Geriatric Cognitive Disorders 2004:17 (suppl 1) 40-48.

2. Sadowsky C, Edwards KR, Etemad B, Falow M.  Maintaining effective treatment in dementia:  A case series on patients switched to rivastigmine. Primary Care Psychiatry 2004:9 71-75.

3. Edwards KR, Koumaras B, Chen M, Gunay I, Mirski D.  Long-Term Effects of  Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease: Results of a 52-Week Open-Label Study  Clinical Drug Investigation 2005: 25 507-515

4. Grossberg G, Edwards K, Zhao Q.  Galantamine with Adjunctive memantine: Combined Effects on Brain Nicotinic Acetylcholine Receptors and N-methyl-D aspartate (NMDA) Receptors may Improve Alzheimer’s Disease Symptomatology  J. Clin. Pharmacol  2006 46: 17S - 26S.

5. Bhasin M,  Rowan E. Edwards K, McKeith IG.  Cholinesterase inhibitors in Dementia with Lewy Bodies – A comparative analysis.  Int J Ger Psychiatry  2007: 22; 890 – 895

6. Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M Pasquier F, Johnson S.  Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies:  A 24-Week Open Label Study.   Dem Ger Cog Dis. 23: 301-305, 2007

7. Southern Saratoga Chamber Newsletter 2012 "Learn from the Experts - What is Dementia and Alzheimer's Disease ? by Keith Edwards, MD"  Bridges Volume 26 No 2 Summer 2012 - Page 4.